Semaglutide, marketed as Wegovy, shows weight-related benefits for children as young as 6 with obesity, according to results from the phase III STEP Young trial. MedPage Today reports that children aged 6 to 11 lost significant weight with the medication, with outcomes assessed over 68 weeks.
Quartz focuses on the trial’s headline results, saying body-mass index (BMI) fell by an estimated 17.4% with semaglutide compared with an increase of 2.2% with placebo at week 68 among children 6 to under 12. Both outlets describe the study as evidence supporting GLP-1 weight-loss treatment in a younger age group than previously established in major trials.
MedPage Today additionally frames the reporting from a conference setting in National Harbor, Maryland, while Quartz summarizes the comparative efficacy numbers more directly. Neither source description here emphasizes safety outcomes or long-term follow-up beyond the reported week-68 results.